Sanyou Biopharmaceuticals Upgrades AI-STAL Platform for Intelligent Biologics Discovery

Sanyou Biopharmaceuticals has introduced AI-STAL 2.0, the latest version of its AI Super-Trillion Antibody Library, announced in a press release. The upgraded platform integrates artificial intelligence throughout drug discovery, from target identification to molecule evaluation, aiming to improve efficiency and accuracy in biologics research.

The AI-STAL 2.0 platform includes a dedicated AI system referred to as the "Super Brain," which supports intelligent workflows for target discovery, molecule generation, optimization, and evaluation. It combines genomic, proteomic, and metabolomic data with proprietary knowledge graphs to identify high-value clinical targets. Large-scale AI models enable de novo antibody sequence generation, accelerating discovery and validation.

The platform also provides AI-based optimization covering humanization, affinity maturation, and pharmacokinetic improvement. Evaluation processes include assessments of affinity, immunogenicity, and stability to ensure safety and performance. AI-STAL 2.0 now hosts more than 10 trillion molecules across fully human, single-domain, immune, and novel molecular libraries.

According to the company, AI-STAL has supported over 1,000 molecular discovery projects, with hundreds advancing to preclinical stages. The platform is designed to support various therapeutic modalities, including monoclonal and bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapies.